Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT Inc (XENT) Stock

Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $37.66, for a total transaction of $483,290.78. Following the transaction, the chief financial officer now directly owns 36,265 shares of the company’s stock, valued at $1,365,739.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Intersect ENT stock opened at $36.60 on Friday. The stock has a market capitalization of $1,113.21, a PE ratio of -65.36 and a beta of 0.75. Intersect ENT Inc has a 52-week low of $15.90 and a 52-week high of $40.00.

How to Become a New Pot Stock Millionaire

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.06. The company had revenue of $29.53 million during the quarter, compared to analysts’ expectations of $29.45 million. Intersect ENT had a negative net margin of 16.99% and a negative return on equity of 14.40%. sell-side analysts forecast that Intersect ENT Inc will post -0.59 EPS for the current year.

XENT has been the subject of a number of research analyst reports. BidaskClub cut shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday. JPMorgan Chase raised shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 price objective on shares of Intersect ENT in a research report on Monday, December 11th. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Intersect ENT in a research report on Thursday, March 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $33.38.

Several institutional investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new stake in shares of Intersect ENT in the fourth quarter valued at about $370,000. Wolverine Trading LLC bought a new stake in shares of Intersect ENT in the fourth quarter valued at about $341,000. Elkfork Partners LLC bought a new stake in shares of Intersect ENT in the fourth quarter valued at about $237,000. TIAA CREF Investment Management LLC boosted its position in shares of Intersect ENT by 7.7% in the fourth quarter. TIAA CREF Investment Management LLC now owns 137,428 shares of the medical equipment provider’s stock valued at $4,453,000 after acquiring an additional 9,792 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of Intersect ENT by 333.9% in the fourth quarter. Teachers Advisors LLC now owns 288,732 shares of the medical equipment provider’s stock valued at $9,355,000 after acquiring an additional 222,195 shares during the period. 84.49% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT Inc (XENT) Stock” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3337570/jeryl-l-hilleman-sells-12833-shares-of-intersect-ent-inc-xent-stock.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Sojourn Reaches Market Capitalization of $44,783.00
Sojourn Reaches Market Capitalization of $44,783.00
Nework Hits 24-Hour Volume of $3.99 Million
Nework Hits 24-Hour Volume of $3.99 Million
Brokerages Anticipate FLIR Systems  to Post $0.43 EPS
Brokerages Anticipate FLIR Systems to Post $0.43 EPS
Strayer Education  Given Consensus Rating of “Buy” by Brokerages
Strayer Education Given Consensus Rating of “Buy” by Brokerages
Lionsgate  Given Average Rating of “Buy” by Analysts
Lionsgate Given Average Rating of “Buy” by Analysts
 Reaches Market Cap of $0.00
Reaches Market Cap of $0.00


© 2006-2018 Ticker Report. Google+.